Leap Therapeutics (LPTX) Competitors $0.36 -0.09 (-19.56%) Closing price 03/27/2025 04:00 PM EasternExtended Trading$0.34 -0.03 (-7.89%) As of 08:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock LPTX vs. OKUR, OCX, ANEB, TNYA, GANX, ALTS, APLT, IKNA, CNTX, and VHAQShould you be buying Leap Therapeutics stock or one of its competitors? The main competitors of Leap Therapeutics include OnKure Therapeutics (OKUR), OncoCyte (OCX), Anebulo Pharmaceuticals (ANEB), Tenaya Therapeutics (TNYA), Gain Therapeutics (GANX), Janone (ALTS), Applied Therapeutics (APLT), Ikena Oncology (IKNA), Context Therapeutics (CNTX), and Viveon Health Acquisition (VHAQ). These companies are all part of the "pharmaceutical products" industry. Leap Therapeutics vs. OnKure Therapeutics OncoCyte Anebulo Pharmaceuticals Tenaya Therapeutics Gain Therapeutics Janone Applied Therapeutics Ikena Oncology Context Therapeutics Viveon Health Acquisition OnKure Therapeutics (NASDAQ:OKUR) and Leap Therapeutics (NASDAQ:LPTX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their community ranking, valuation, institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and media sentiment. Do analysts recommend OKUR or LPTX? OnKure Therapeutics currently has a consensus target price of $32.33, indicating a potential upside of 589.41%. Leap Therapeutics has a consensus target price of $4.92, indicating a potential upside of 1,247.77%. Given Leap Therapeutics' higher probable upside, analysts clearly believe Leap Therapeutics is more favorable than OnKure Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score OnKure Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 2 Strong Buy rating(s) 3.40Leap Therapeutics 0 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.25 Do institutionals & insiders believe in OKUR or LPTX? 91.0% of OnKure Therapeutics shares are owned by institutional investors. Comparatively, 30.5% of Leap Therapeutics shares are owned by institutional investors. 17.9% of OnKure Therapeutics shares are owned by company insiders. Comparatively, 5.4% of Leap Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has more risk and volatility, OKUR or LPTX? OnKure Therapeutics has a beta of 0.28, meaning that its stock price is 72% less volatile than the S&P 500. Comparatively, Leap Therapeutics has a beta of 0.35, meaning that its stock price is 65% less volatile than the S&P 500. Does the media favor OKUR or LPTX? In the previous week, Leap Therapeutics had 5 more articles in the media than OnKure Therapeutics. MarketBeat recorded 9 mentions for Leap Therapeutics and 4 mentions for OnKure Therapeutics. Leap Therapeutics' average media sentiment score of 0.61 beat OnKure Therapeutics' score of -0.01 indicating that Leap Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment OnKure Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Leap Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Is OKUR or LPTX more profitable? OnKure Therapeutics' return on equity of -51.17% beat Leap Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets OnKure TherapeuticsN/A -51.17% -47.11% Leap Therapeutics N/A -116.24%-93.18% Which has better earnings and valuation, OKUR or LPTX? OnKure Therapeutics is trading at a lower price-to-earnings ratio than Leap Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOnKure TherapeuticsN/AN/A-$77.39M-$6.57-0.71Leap TherapeuticsN/AN/A-$81.41M-$1.93-0.19 Does the MarketBeat Community favor OKUR or LPTX? Leap Therapeutics received 287 more outperform votes than OnKure Therapeutics when rated by MarketBeat users. However, 100.00% of users gave OnKure Therapeutics an outperform vote while only 68.37% of users gave Leap Therapeutics an outperform vote. CompanyUnderperformOutperformOnKure TherapeuticsOutperform Votes7100.00% Underperform VotesNo VotesLeap TherapeuticsOutperform Votes29468.37% Underperform Votes13631.63% SummaryOnKure Therapeutics beats Leap Therapeutics on 9 of the 16 factors compared between the two stocks. Remove Ads Get Leap Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LPTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LPTX vs. The Competition Export to ExcelMetricLeap TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$13.98M$6.92B$5.65B$8.06BDividend YieldN/A2.72%4.57%4.01%P/E Ratio-0.197.2023.1419.03Price / SalesN/A226.01385.7893.17Price / CashN/A65.6738.1634.64Price / Book0.166.476.934.33Net Income-$81.41M$141.90M$3.20B$247.06M7 Day Performance-9.03%-3.20%-2.30%-0.37%1 Month Performance-21.26%-5.64%2.86%-3.85%1 Year Performance-86.29%-7.47%10.66%1.27% Leap Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LPTXLeap Therapeutics2.494 of 5 stars$0.36-19.6%$4.92+1,247.8%-86.9%$13.98MN/A-0.1940Earnings ReportUpcoming EarningsAnalyst ForecastShort Interest ↓News CoverageGap DownHigh Trading VolumeOKUROnKure Therapeutics2.6687 of 5 stars$4.82+4.6%$34.33+612.3%N/A$64.76MN/A-0.40N/AGap UpOCXOncoCyte2.5537 of 5 stars$3.70-1.1%$4.42+19.4%+8.1%$64.58M$709,000.000.00120Earnings ReportAnalyst ForecastShort Interest ↑ANEBAnebulo Pharmaceuticals2.9872 of 5 stars$1.56-8.8%$8.00+412.8%-49.6%$64.09MN/A-5.574Short Interest ↓Positive NewsGap DownHigh Trading VolumeTNYATenaya Therapeutics4.1274 of 5 stars$0.73+4.4%$6.25+756.2%-86.6%$63.94MN/A-0.51110Short Interest ↓Analyst RevisionGap DownGANXGain Therapeutics3.23 of 5 stars$2.40+13.7%$8.20+241.7%-44.5%$63.66M$50,000.00-2.1820Earnings ReportHigh Trading VolumeALTSJanoneN/A$4.52-2.6%N/AN/A$63.59M$7.11M0.00170Short Interest ↓APLTApplied Therapeutics4.2755 of 5 stars$0.55+6.4%$6.10+1,016.4%-92.1%$63.58M$-212,000.00-0.3430Upcoming EarningsPositive NewsIKNAIkena Oncology2.9701 of 5 stars$1.31-2.2%$3.00+129.0%-4.3%$63.22M$659,000.00-1.0770Positive NewsHigh Trading VolumeCNTXContext Therapeutics2.2992 of 5 stars$0.84+19.2%$6.33+652.6%-46.6%$63.11MN/A-0.927VHAQViveon Health AcquisitionN/A$11.00flatN/AN/A$62.26MN/A0.002High Trading Volume Remove Ads Related Companies and Tools Related Companies OnKure Therapeutics Alternatives OncoCyte Alternatives Anebulo Pharmaceuticals Alternatives Tenaya Therapeutics Alternatives Gain Therapeutics Alternatives Janone Alternatives Applied Therapeutics Alternatives Ikena Oncology Alternatives Context Therapeutics Alternatives Viveon Health Acquisition Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LPTX) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Leap Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Leap Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
